Mounjaro in Barcelona: indications, benefits, and medical follow-up

Why there's so much talk about Mounjaro

If GLP-1 receptor agonists represented a leap forward in weight medicine, Mounjaro (tirzepatide) has been the next. Tirzepatide is a dual agonist of GIP and GLP-1 receptors, which in clinical studies has translated into greater weight loss than observed with semaglutide in many patients and significant improvements in glycemic control in type 2 diabetes.

It is a powerful drug. Like all powerful drugs, it needs to be used for the correct indication, at the appropriate dose, and with strict follow-up. At Santé Clinics, we integrate tirzepatide protocols into a comprehensive medical-nutritional program, with initial assessment, dose titration, body composition monitoring, and an exercise plan. This article explains what it is, how it works, for whom it is indicated, and how we approach it.

What is tirzepatide

Tirzepatide is a synthetic molecule that simultaneously activates two hormonal receptors:

• GLP-1 receptor (glucagon-like peptide-1): increases satiety, slows gastric emptying, improves glucose-dependent insulin secretion.
• GIP receptor (glucose-dependent insulinotropic polypeptide): enhances insulin response and, according to available data, contributes to the effect on appetite and body composition.

Dual activation amplifies metabolic effects compared to single GLP-1 receptor agonists. It is administered by subcutaneous injection, once a week, with progressive dose titration to improve tolerance.

Authorized indications

Mounjaro is authorized for its approved indications in various markets, primarily:

• Type 2 diabetes mellitus in combination with diet and exercise.
• Treatment of overweight and obesity in adults with BMI ≥30 (obesity) or BMI ≥27 with at least one associated comorbidity (hypertension, dyslipidemia, type 2 diabetes, sleep apnea, established cardiovascular disease).

It is important to emphasize what it is not: it is not a drug “to look better for summer,” it is not an “aesthetic” drug, it is not prescribed to lose the last few pounds in a normal BMI. That indication does not exist and should not exist.

Documented benefits

In clinical trials and post-marketing experience, tirzepatide has shown:

• Significant weight loss in patients with obesity: in pivotal studies, average reductions of 15–22% of body weight at 72 weeks, depending on the dose.
• Improvement in glycemic control in type 2 diabetes: significant HbA1c reductions.
• Improvement in lipid profile.
• Reduction in blood pressure.
• Improvement in fatty liver markers.

The benefits are dose-dependent and depend, above all, on nutritional and exercise support.

For whom it is indicated and for whom it is not

It is indicated for:

• Adults with obesity (BMI ≥30) with or without comorbidities.
• Adults with overweight (BMI ≥27) and at least one metabolic or cardiovascular comorbidity.
• Patients with type 2 diabetes in whom glycemic control is not optimal with other measures.
• Patients who have attempted weight loss with diet and exercise and need structured pharmacological support.

It is not indicated for:

• Pregnancy, lactation, and women planning pregnancy in the short term.
• Personal or family history of medullary thyroid carcinoma or MEN-2 (multiple endocrine neoplasia type 2 syndrome).
• History of severe pancreatitis.
• Severe eating disorders without coordination with mental health.
• Type 1 diabetes (not the indication).
• Hypersensitivity to the active substance.
• Adults with normal weight (BMI <25) and no medical indication.

Side effects and management

The most common adverse effects are digestive and usually appear during dose titration:

• Nausea, especially at the beginning and when increasing doses.
• Diarrhea or constipation.
• Reflux and postprandial fullness.
• Mild abdominal pain.
• Significant decrease in appetite (desired effect, but to be monitored).

They are usually mild-to-moderate and improve with:

• Slow dose titration (this is the key tool: increasing the dose when the body tolerates it, not by calendar).
• Nutritional adjustments (smaller meals, less heavy fats, hydration).
• Occasional antiemetics if necessary.

Less common but important adverse effects to consider:

• Acute pancreatitis: reason to suspend and seek urgent medical attention for persistent severe abdominal pain.
• Allergic reactions.
• Hypoglycemia if combined with sulfonylureas or insulin.
• Cholelithiasis and biliary disease.
• Transient worsening of retinopathy in patients with poorly controlled diabetes (ophthalmological monitoring if appropriate).

For all these reasons, medical follow-up is not optional.

How the protocol at Santé works

1. Initial medical consultation with a complete assessment: medical history, background, medication, examination, blood pressure, BMI, abdominal circumference, recent lab tests.
2. Indication: the doctor confirms that you meet the criteria and rules out contraindications.
3. Nutritional consultation (mandatory): personalized plan, protein intake, hydration, digestive management.
4. Start of treatment with progressive titration according to clinical guidelines.
5. Monthly follow-up for the first few months, then as evolution dictates: tolerance, dose, weight, body composition with bioimpedance, nutritional and exercise adjustments.
6. Coordination with body contouring devices if there is skin laxity or tissue redistribution during weight loss (HIFU, INDIBA, mesotherapy, collagen stimulators).
7. Maintenance plan and, in due course, a plan for withdrawal or continuation.

Mounjaro vs Wegovy vs Ozempic

To avoid confusion with brands:

• Ozempic = semaglutide, primary indication type 2 diabetes.
• Wegovy = semaglutide in specific format and dose for obesity.
• Mounjaro = tirzepatide (dual GIP/GLP-1 agonist).
• Zepbound (where available) = tirzepatide in specific presentation for obesity.

The choice is not made by trend or name. It is made by the doctor based on the patient, comorbidities, prior tolerance, availability, and response. For many patients, semaglutide is excellent. For others, the additional potency of tirzepatide makes the difference.

What tirzepatide does not solve

• It does not build muscle: you build it with protein and strength training.
• It does not teach habits: the nutritionist and time teach them.
• It does not correct skin laxity associated with significant weight loss: for that, body contouring devices.
• It is not an eternal shortcut: what the patient learns during treatment is important.

Frequently asked questions

Do I need to be diabetic to use Mounjaro? No. The indication for obesity and overweight with comorbidities exists.

Is it forever? It depends on the case. Some patients use it for months, others for years, others indefinitely. Medical evolution decides.

Will I regain the weight if I stop? If nutrition, exercise, and habits have not been worked on during treatment, yes, it is likely. That's why we insist on accompaniment.

Is the medical consultation to assess treatment free? No. It is a medical consultation with its corresponding cost, which we will confirm when you book.

How much weight is lost? Variable, but clinical data place the average between 15% and 22% of body weight at 72 weeks in obese patients, with diet and exercise.

What happens to muscle mass? If protein and strength exercise are not taken care of, it is lost. That is why nutritional follow-up and exercise are mandatory in our protocols.

Book your medical assessment for Mounjaro at Santé

The right question is not “can I get Mounjaro?” It’s “do I need it and how do we do it right?” We start with a medical and nutritional consultation that determines if it’s for you.

Book an appointment via WhatsApp at +34 699 14 58 87. Avenida Diagonal 384, Barcelona.